We are passionate about partnering with innovative biopharmaceutical companies and researchers to advance their drug discovery and development efforts.

Our goal is to collaborate in making new-to-the-world discoveries, creating valuable intellectual property, accelerating and enabling achievement of development milestones, and paving the way for improved patient outcomes and commercial success.

Collaborations may be focused on specific challenges such as illuminating disease mechanisms, identifying novel drug targets, or discovering biomarkers for predicting and measuring clinical outcomes ⎼ or may span multiple steps of a development program.

Inquiries about partnering may be directed to Randolph Floyd, CEO of CellPrint.